Sanofi's fitusiran significantly reduced bleeding in a Phase III multinational study in adults and adolescents with hemophilia A or B, with or without inhibitors.
NIAID has launched an early-stage clinical trial to evaluate an investigational preventive vaccine for Epstein-Barr virus (EBV).
A new study shows treatment with IVIG shows promise for children and young adults with Down syndrome regression disorder (DSRD).
Despite technical challenges, some companies are working on making a combination COVID and flu vaccine.
New data from a Phase II clinical trial of Valneva SE and Pfizer Inc.’s Lyme disease vaccine candidate, VLA15, shows it produced strong immune responses, prompting preparations for a Phase III study in the third quarter of 2022.
NIAID has launched a Phase I clinical trial evaluating three experimental HIV vaccines based on a mRNA platform — a technology used in several approved COVID-19 vaccines.
A clinical trial of the Vaxina (the CF33-hNIS virus) designed to kill cancer cells has begun.
According to CDC, this season’s influenza (flu) vaccines offered meager protection against mild cases of influenza.
FDA has given fast track approval for Bluebird Bio’s Zynteglo, a treatment designed to tackle the rare condition known as transfusion-dependent beta-thalassemia (TDBT).
A cross-disciplinary coalition of experts from academic centers across the United States is partnering with NIH, FDA, pharmaceutical companies and nonprofit organizations to identify new targets for therapies for autoimmune-meditated diseases.
Researchers in a study funded by the National Institute of Allergy and Infectious Diseases and the National Institutes of Health have developed an influenza (flu) vaccine administered through the nose that has been constructed with nanoparticles and offers stronger protection.
Proposed rules revising the Medicare Hospital Outpatient Prospective Payment System (OPPS) and the Medicare Ambulatory Surgical Center (ASC) services, along with new physician fee schedule (PFS) rule sets will significantly impact providers in 2023.
